Synthesis and cellular uptake of 2'-substituted analogues of (e)-5-(2- [125i]iodovinyl)-2'-deoxyuridine in tumor cells transduced with the herpes simplex type-1 thymidine kinase gene. Evaluation as probes for monitoring gene therapy

Journal of Medicinal Chemistry

Volumn 40, Issue 14, 1997, Pages 2184-2190

  Morin, Kevin W ^a   Atrazheva, Elena D ^a   Knaus, Edward E ^a   Wiebe, Leonard I ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 IODOVINYL) 2' DEOXYURIDINE; 5 (2 IODOVINYL) 2' FLUORO 2' DEOXYARABINOURIDINE; 5 (2 IODOVINYL) 2' FLUORO 2' DEOXYURIDINE; 5 (2 IODOVINYL)URACIL ARABINOSIDE; ANTIVIRUS AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; DRUG UPTAKE; EXPRESSION VECTOR; GENE THERAPY; HERPES SIMPLEX VIRUS 1; ISOTOPE LABELING; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE; NONHUMAN;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL TRANSPORT; CELL LINE; GENE THERAPY; GENES, VIRAL; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; IDOXURIDINE; INDICATORS AND REAGENTS; IODINE RADIOISOTOPES; ISOTOPE LABELING; KINETICS; MICE; MOLECULAR STRUCTURE; MOLONEY MURINE LEUKEMIA VIRUS; MONITORING, PHYSIOLOGIC; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE KINASE; TRANSFECTION;

EID: 0030793291     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9606406     Document Type: Article

References (37)

1. Mullen, C. A. Metabolic suicide genes in gene therapy. Pharmacol. Ther. 1994, 63, 199-207.
2. Moolten, F. Tumor sensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986, 46, 5276-5281.
3. Oldfield, E. H.; Ram, Z.; Culver, K. W.; Blaese, R. M.; DeVroom, H. L.; Anderson, W. F. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 1993, 4, 60-69.
4. De Clercq, E. Biochemical aspects of the selective antiherpes activity of nucleoside analogues. Biochem. Pharmacol. 1984, 33, 2159-2169.
5. Fyfe, J. A.; Keller, P. M.; Furman, P. A.; Miller, R. I.; Ellion, G. B. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J. Biol. Chem. 1978, 253, 8721-8727.
6. Balzarini, J.; Bohman, C.; Walker, R. T.; De Clercq, E. Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells. Mol. Pharmacol. 1994, 45, 1253-1258.
7. Culver, K. W.; Ram, Z.; Walbridge, S.; Ishii, H.; Oldfield, E. H.; Blaese, R. M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992, 256, 1550-1552.
8. Balzarini, J.; Bohman, C.; De Clercq, E. Differential mechanism of cytostatic effect of (E)-5-12-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2. J. Biol. Chem. 1993, 268, 6332-6337.
9. Balzarini, J.; De Clercq, E.; Ayusawa, D.; Seno, T. Murine mammary FM3A carcinoma cells transformed with the herpes simplex virus type 1 thymidine kinase gene are highly sensitive to the growth-inhibitory properties of (E)-5-(2-bromovinyl)-2′-deoxyuridine and related compounds. FEBS Lett. 1985, 185, 95-100.
10. Balzarini, J.; De Clercq, E.; Verbruggen, A.; Ayusawa, D.; Seno, T. Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2′-deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex type 1 thymidine kinase gene. Mol. Pharmacol. 1985, 28, 581-587.
11. Hirota, Y.; Arao, Y.; Matsumoto, A.; Nu, S.; Wataya, Y. Different mechanisms of inhibition of DNA synthesis by (E)-5-(2-bromovinyl)-2′-deoxyuridine in cells transfected with gene for thymidine kinase of herpes simplex virus type 1 and in cells infected with the virus. Nucleosides Nucleotides 1995, 14, 2079-2087.
12. Balzarini, J.; De Clercq, E.; Verbruggen, A.; Ayusawa, D.; Shimizu, K.; Seno, T. Thymidylate synthase is the principle target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2′-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex type 1 or type 2 thymidine kinase gene. Mol. Pharmacol. 1987, 32, 410-416.
13. 131I]iodovinyl)-2′-deoxyuridine in dogs. Antimicrob. Agents Chemother. 1986, 29, 320-324.
14. Iwashina, T.; Tovell, D. R.; Xu, L.; Tyrrell, D. L.; Knaus, E. E.; Wiebe, L. I. Synthesis and antiviral activity of IVFRU, a potential probe for the non-invasive diagnosis of herpes simplex encephalitis. Drug Des. Delivery 1988, 3, 309-321.
15. Perlman, M. E.; Watanabe, K. A.; Schinazi, R. F.; Fox, J. J. Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl (cytosines and related pyrimidine nucleosides as potential antiviral agents. J. Med. Chem. 1985, 28, 741-748.
16. Machida, H.; Sakata, S. In vitro and in vivo antiviral activity of 1-β-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and related compounds. Antiviral Res. 1984, 4, 135-141.
17. Ram, Z.; Culver, K. W.; Walbridge, S.; Blaese, R. M.; Oldfield, E. H. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 1993, 53, 83-88.
18. Tjuvajev, J. G.; Stockhammer, G.; Desai, R.; Uehara, H.; Watanabe, K.; Gansbacher, B.; Blasberg, R. G. Imaging the expression of transfected genes in vivo. Cancer Res. 1995, 55, 6126-6132.
19. Tjuvajev, J. G.; Finn, R.; Watanabe, K.; Joshi, R.; Oku, T.; Kennedy, J.; Beattie, B.; Koutcher, J.; Larson, S.; Blasberg, R. G. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: A potential method for monitoring clinical gene therapy. Cancer Res. 1996, 65, 4087-4095.
20. Verbruggen, A.; Julien, C.; De Clercq, E.; De Roo, M. Simple quantitative radioiodination of (E)-5-(2-iodovinyl)-2′-deoxyuridine (IVDU) by exchange labelling. Appl. Radiat. Isot. 1986, 37, 355-357.
21. 82Br labelled (E)-5-(2-halovinyl)-2′-deoxyuridines. Int. J. Appl. Radiat. Isot. 1984, 35, 1049-1052.
22. 123I]-1-(β-D-arabinofuranosyl)-5-(E)-(2-iodovinyl)uracil (IVaraU): High yielding radiolabeling via organotin and exchange reactions. Appl. Radiat. Isot. 1994, 45, 795-801.
23. Robins, M. J.; Manfredini, S.; Wood, S. G.; Wankin, R. J.; Rennie, B. A.; Sacks, S. L. Nucleic acid related compounds. 65. New syntheses of 1-(β-D-arabinofuranosyl)-5-(E)-(2-iodovinyl)uracil (IVAraU) from vinylsilane precursors. Radioiodine uptake as a marker for thymidine kinase positive herpes viral infections. J. Med. Chem. 1991, 34, 2275-2280.
24. Crisp, G. T. Synthesis of 5-alkenyl-2′-deoxyuridines via organostannanes. Synth. Commun. 1989, 19, 2117-2123.
25. Aaronson, S. A.; Weaver, C. A. Characterization of murine sarcoma virus (Kirsten) transformation of mouse and human cells. J. Gen. Virol. 1971, 13, 245-252.
26. Freeman, S. M.; Abboud, C. N.; Whartenby, K. A.; Packman, C. H.; Koeplin, D. S.; Moolten, F. L.; Abraham, G. N. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993, 53, 5274-5283.
27. Moolten, F. L.; Wells, J. M. Curability of tumors bearing herpes thymidine kinase genes transferred by retrovirus vectors. J. Natl. Cancer Inst. 1990, 82, 297-300.
28. 131I-labeled (E)-5-(2-iodovinyl)-2′-deoxyuridine in herpes simplex virus-infected cells in vitro. Antimicrob. Agents Chemother. 1984, 25, 476-478.
29. Watanabe, K. A.; Su, T.-L.; Klein, R. S.; Chu, C. K.; Matsuda, A.; Chun, M. W.; Lopez, C.; Fox, J. J. Nucleosides. 123. Synthesis of antiviral nucleosides: 5-Substituted 1-(2-deoxy-2-halogeno-β-D-arabinofuranosyl)cytosines and -uracils. Some structure-activity relationships. J. Med. Chem. 1983, 26, 152-156.
30. Tovell, D. R.; Samuel, J.; Mercer, J. R.; Misra, H. K.; Xu, L.; Wiebe, L. I.; Tyrrell, D. L.; Knaus, E. E. The in vitro evaluation of nucleoside analogues as probes for use in the non-invasive diagnosis of herpes simplex encephalitis. Drug Des. Delivery 1988, 3, 213-221.
31. Gati, W. P.; Knaus, E. E.; Wiebe, L. I. Interaction of 2′-halogeno-2′-deoxyuridines with the human erythrocyte nucleoside transport mechanism. Mol. Pharmacol. 1983, 23, 146-152.
32. Gati, W. P.; Misra, H. K.; Knaus, E. E.; Wiebe, L. I. Structural modifications at the 2′- and 3′-positions of some pyrimidine nucleosides as determinations of their interaction with the mouse erythrocyte nucleoside transporter. Biochem. Pharmacol. 1984, 33, 3325-3331.
33. Balzarini, J.; Morin, K. W.; Knaus, E. E.; Wiebe, L. I.; De Clercq, E. Novel (E)-5-(2-iodovinyl)-2′-deoxyuridine derivatives as potential cytostatic agents against herpes simplex virus thymidine kinase gene transfected tumors. Gene Therapy 1995, 2, 317-322.
34. Balzarini, J.; De Clercq, E. Inhibitory effects of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and related compounds on herpes simplex virus (HSV)-infected cells and HSV thymidine kinase gene-transformed cells. Methods Find. Exp. Clin. Pharmacol. 1989, 11, 379-389.
35. 131I-labeled 5-halo-1-(2-fluoro-2-deoxy-β-D-ribofuranosyl)uracils. J. Med. Chem. 1989, 32, 1289-1294.
36. Cunico, R. F.; Clayton, F. J. trans-β-Trimethylsilylvinyllithium. J. Org. Chem. 1976, 41, 1480-1482.
37. Watanabe, K. A.; Su, T-L; Reichman, U.; Greenberg, N.; Lopez, C.; Fox, J. J. Nucleosides. 129. Synthesis of antiviral nucleosides: 5-Alkenyl-1-2-deoxy-2-fluoro-β-D-arabinofuranosyl)-uracils. J. Med. Chem. 1984, 27, 91-94.